Arvinas Inc logo

ARVN - Arvinas Inc Share Price

$63.63 0.5  0.8%

Last Trade - 07/05/21

Mid Cap
Market Cap £2.23bn
Enterprise Value £1.77bn
Revenue £15.1m
Position in Universe 1856th / 6858
Unlock ARVN Revenue
Relative Strength (%)
1m -3.59%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -31.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 6.67 7.58 14.3 43.0 21.8 17.8 15.1 +34.5%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, ArvinasInc revenues decreased 11% to $5.5M. Net loss increased 88%to $41M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Higher net loss reflects Research anddevelopment increase of 60% to $34.9M (expense), Generaland administrative increase of 55% to $12.3M (expense),Interest income decrease of 65% to $450K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ARVN Revenue Unlock ARVN Revenue

Net Income

ARVN Net Income Unlock ARVN Revenue

Normalised EPS

ARVN Normalised EPS Unlock ARVN Revenue

PE Ratio Range

ARVN PE Ratio Range Unlock ARVN Revenue

Dividend Yield Range

ARVN Dividend Yield Range Unlock ARVN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ARVN EPS Forecasts Unlock ARVN Revenue
Profile Summary

Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Company is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. It is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. It seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated December 9, 2014
Public Since September 27, 2018
No. of Shareholders: 83
No. of Employees: 179
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 48,988,096
Free Float (0.0%)
Eligible for
ARVN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ARVN
Upcoming Events for ARVN
Thursday 3rd June, 2021 Estimate
Arvinas Inc Annual Shareholders Meeting
Tuesday 8th June, 2021
Arvinas Inc Annual Shareholders Meeting
Monday 2nd August, 2021 Estimate
Q2 2021 Arvinas Inc Earnings Release
Wednesday 3rd November, 2021 Estimate
Q3 2021 Arvinas Inc Earnings Release
Frequently Asked Questions for Arvinas Inc
What is the Arvinas Inc share price?

As of 07/05/21, shares in Arvinas Inc are trading at $63.63, giving the company a market capitalisation of £2.23bn. This share price information is delayed by 15 minutes.

How has the Arvinas Inc share price performed this year?

Shares in Arvinas Inc are currently trading at $63.63 and the price has moved by 16.47% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arvinas Inc price has moved by -18.78% over the past year.

What are the analyst and broker recommendations for Arvinas Inc?

Of the analysts with advisory recommendations for Arvinas Inc, there are there are currently 4 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arvinas Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Arvinas Inc next release its financial results?

Arvinas Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Arvinas Inc dividend yield?

Arvinas Inc does not currently pay a dividend.

Does Arvinas Inc pay a dividend?

Arvinas Inc does not currently pay a dividend.

When does Arvinas Inc next pay dividends?

Arvinas Inc does not currently pay a dividend.

How do I buy Arvinas Inc shares?

To buy shares in Arvinas Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arvinas Inc?

Shares in Arvinas Inc are currently trading at $63.63, giving the company a market capitalisation of £2.23bn.

Where are Arvinas Inc shares listed? Where are Arvinas Inc shares listed?

Here are the trading details for Arvinas Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ARVN
What kind of share is Arvinas Inc?

Based on an overall assessment of its quality, value and momentum, Arvinas Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arvinas Inc share price forecast 2021?

Shares in Arvinas Inc are currently priced at $63.63. At that level they are trading at 76.8% discount to the analyst consensus target price of 0.00.

Analysts covering Arvinas Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.521 for the next financial year.

How can I tell whether the Arvinas Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arvinas Inc. Over the past six months, the relative strength of its shares against the market has been 0.145k%. At the current price of $63.63, shares in Arvinas Inc are trading at 28.45% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arvinas Inc PE Ratio?

We were not able to find PE ratio data for Arvinas Inc.

Who are the key directors of Arvinas Inc?

Arvinas Inc's management team is headed by:

Ronald Peck - OTH
Timothy Shannon - CHM
Sean Cassidy - CFO
John Houston - PRE
Ian Taylor - CSO
Edward Kennedy - IND
Bradley Margus - IND
Briggs Morrison - IND
Linda Bain - DRC
Wendy Dixon - DRC
Who are the major shareholders of Arvinas Inc?

Here are the top five shareholders of Arvinas Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 9.23% (4.52m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 7.5% (3.67m shares)
Canaan Partners Venture Capital
Percentage owned: 7.33% (3.59m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.09% (2.49m shares)
New Leaf Venture Partners Venture Capital
Percentage owned: 4.66% (2.28m shares)
Similar to ARVN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.